Andreas Engert

Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.

B. Coiffier, Corinne Haïoun, Nicolas Ketterer et al. · PubMed · 1998 · 896 citations

Autologous Stem-Cell Transplantation As First-Line Therapy in Peripheral T-Cell Lymphomas: Results of a Prospective Multicenter Study

Peter Reimer, Thomas Rüdiger, Eva Geissinger et al. · Journal of Clinical Oncology · 2008 · 422 citations

Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG)

Andreas Josting, Christian Rudolph, MY Mapara et al. · Annals of Oncology · 2004 · 157 citations · Full text

Lymphoid Neoplasia, Large Multicenter Study, Surgical Oncology +6

Multicenter Phase II Trial of Immunotherapy With the Humanized Anti-CD22 Antibody, Epratuzumab, in Combination With Rituximab, in Refractory or Recurrent Non-Hodgkin's Lymphoma

Sandra J. Strauss, F. Morschhauser, Jürgen Rech et al. · Journal of Clinical Oncology · 2006 · 148 citations · Full text

Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG)

Lucia Nogová, Thorsten Reineke, Hans Theodor Eich et al. · Annals of Oncology · 2005 · 137 citations · Full text

Field Radiotherapy, Lymphoid Neoplasia, Surgical Oncology +9